Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Farheen Chunara, Mansi R. Shah, Nishi Shah, Jessica Kent, Ghulam Rehman Mohyuddin, Sabarinath V Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2024) 144 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2024-201599

Published: 2024

Journal Articles

Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis

Edward R Scheffer Cliff, Martin F Kaiser, Douglas W. Sborov, Rafael Fonseca, Ghulam Rehman Mohyuddin

Blood (2024) 144 (Supplement 1): 3792.6.

https://doi.org/10.1182/blood-2024-207365

Published: 2024

Journal Articles

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Alissa Visram, Rajshekhar Chakraborty, Gregory R Pond, Hsien Seow, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alejandro Garcia-Horton, Rafael Fonseca, Hira Mian

Blood (2024) 144 (Supplement 1): 5170.3.

https://doi.org/10.1182/blood-2024-200956

Published: 2024

Journal Articles

Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Katherine Berger, Ryan Winborg, Mason S. Barnes, Jorge Arturo Hurtado Martinez, Jay R. Hydren, Douglas W Sborov, Amandeep Godara, Brian McClune, Christopher Booth, Edward R Scheffer Cliff

Blood (2024) 144 (Supplement 1): 2281.

https://doi.org/10.1182/blood-2024-208803

Published: 2024

Journal Articles

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Sharmilee Nuli, Rajshekhar Chakraborty, Al-Ola Abdallah, Suzanne Lentzsch, Evguenia Ouchveridze, Douglas W Sborov, Amandeep Godara, Brian McClune, Ah-Reum Jeong, Samuel M. Rubinstein, Aaron Goodman, Ghulam Rehman Mohyuddin

Blood (2024) 144 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2024-203731

Published: 2024

Journal Articles

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Gliceida Galarza Fortuna, Karen Sweiss, Matias Sanchez, Hira Mian, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2024-208861

Published: 2024

Journal Articles

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Jehad Almasri, Bashar Hasan, Zin Tarakji, Faris W. Naffa', Lynn Warner, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 6986.

https://doi.org/10.1182/blood-2024-206645

Published: 2024

Journal Articles

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Karen Sweiss, Craig C. Hofmeister, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Damiano Rondelli, Danny Hadidi, David Chan, Matias Eugenio Sanchez, Min Hai, Mitch A. Phelps, Chukwuemeka Uzoka, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2023-191148

Published: 2023

Journal Articles

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine Abdallah, Greg Calip, Xiaoyan Wang, Christina Parrinello, Doug Sborov

Blood (2023) 142 (Supplement 1): 1068.

https://doi.org/10.1182/blood-2023-185136

Published: 2023

Journal Articles

Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series

Douglas Peters, Victoria A. Vardell, Gliceida Galarza Fortuna, Sterling Rosqvist, Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Brian McClune, Amandeep Godara, Ghulam Rehman Mohyuddin, Matthew F Covington, Douglas Sborov

Blood (2023) 142 (Supplement 1): 6630.

https://doi.org/10.1182/blood-2023-179287

Published: 2023

Journal Articles

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Edward R Scheffer Cliff, Mark McGuire, Ghulam Rehman Mohyuddin, Aaron Seth Kesselheim, William B Feldman

Blood (2023) 142 (Supplement 1): 5086.

https://doi.org/10.1182/blood-2023-190372

Published: 2023

Journal Articles

Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias

Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Meghan Vigil, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Douglas Sborov

Blood (2023) 142 (Supplement 1): 6623.

https://doi.org/10.1182/blood-2023-174123

Published: 2023

Journal Articles

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

George Mellgard, Molly Gilligan, Edward R Scheffer Cliff, Divaya Bhutani, Ghulam Rehman Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2023) 142 (Supplement 1): 4768.

https://doi.org/10.1182/blood-2023-174908

Published: 2023

Journal Articles

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Joshua White, Sara Zhukovsky, Edward R Scheffer Cliff, Rajshekhar Chakraborty, Luciano Costa, Oliver Van Oekelen, Doug Sborov, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 2402.

https://doi.org/10.1182/blood-2023-185175

Published: 2023

Journal Articles

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy M Schmidt, Rafael Fonseca, Doug Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2023-180271

Published: 2023

Journal Articles

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Sterling Rosqvist, Victoria A. Vardell, Eric Anto, Gliceida Galarza Fortuna, Douglas Peters, Charlotte B Wagner, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Michael R. Savona, Kelley Julian, Brian McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Muhamed Baljevic, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4718.

https://doi.org/10.1182/blood-2023-190746

Published: 2023

Journal Articles

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Radhakrishnan, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Meera Mohan

Blood (2023) 142 (Supplement 1): 358.

https://doi.org/10.1182/blood-2023-182695

Published: 2023

Journal Articles

Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals

Lama Sawalha, Ghulam Rehman Mohyuddin, Aaron M. Goodman, Nico Gagelmann, Amar H. Kelkar, Samer Al Hadidi

Blood (2022) 140 (Supplement 1): 5092–5093.

https://doi.org/10.1182/blood-2022-157443

Published: 2022

Journal Articles

Attrition and Withdrawal Amongst Patients with Multiple Myeloma Participating in Randomized Clinical Trials: A Systematic Review

Stijn Hentzen, Tomer Meirson, Kelly Koehn, Aaron M Goodman, Rajshekhar Chakraborty, Vinay Prasad, Douglas W. Sborov, Ghulam Rehman Mohyuddin

Blood (2022) 140 (Supplement 1): 7950–7951.

https://doi.org/10.1182/blood-2022-159807

Published: 2022

Journal Articles

Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada

Arleigh McCurdy, Hsien Seow, Gregory R Pond, Anastasia Gayowsky, Rajshekhar Chakraborty, Alissa Visram, Rayan Kaedbey, Anita D'Souza, Ghulam Rehman Mohyuddin, Rafael Fonseca, Hira S Mian

Blood (2022) 140 (Supplement 1): 427–429.

https://doi.org/10.1182/blood-2022-157815

Published: 2022

NARROW

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals

Attrition and Withdrawal Amongst Patients with Multiple Myeloma Participating in Randomized Clinical Trials: A Systematic Review

Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only